source stringlengths 2 222 | date stringlengths 19 19 | url stringlengths 22 853 ⌀ | text stringlengths 0 10k ⌀ | title stringlengths 0 701 | context_id stringlengths 1 9 | document_id stringclasses 2
values | document_type stringclasses 2
values |
|---|---|---|---|---|---|---|---|
The Motley Fool | 2023-04-16 10:15:00 | https://www.fool.com/investing/2023/04/16/3-stocks-you-can-keep-forever/ | AbbVie is expected to recover within two years from Humira's patent cliff. Parker-Hannifin is benefiting from increased aerospace spending. | 3 Stocks You Can Keep Forever | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-04-16 07:45:00 | https://www.fool.com/investing/2023/04/16/3-reasons-why-i-regret-selling-abbvie/ | I sold AbbVie for a tidy profit, but simply doing nothing would have been better. Selling means missing out on dividend income as well as share price gains. | 3 Reasons Why I Regret Selling AbbVie | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-04-15 07:35:00 | https://seekingalpha.com/article/4594024-abbvie-stock-investors-trifecta-in-transition | AbbVie is a pharmaceutical giant that is building out its portfolio to look nothing like it did a decade ago, and that is great for investors. In 2023, ABBV's #1 selling drug Humira lost its US patent protection which will be a short-term drag on the company. | AbbVie: An Investor's Trifecta In Transition | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-04-15 06:14:00 | https://www.fool.com/investing/2023/04/15/3-dividend-stocks-to-buy-and-hold-for-the-next-dec/ | AbbVie faces near-term challenges but has solid long-term prospects plus an especially attractive dividend. Gilead Sciences' strong free cash flow should enable the company to continue raising its dividend. | 3 Dividend Stocks to Buy and Hold for the Next Decade | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2023-04-14 10:40:09 | https://www.zacks.com/stock/news/2078797/here-is-what-to-know-beyond-why-abbvie-inc-abbv-is-a-trending-stock | AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. | Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2023-04-12 13:42:15 | https://www.zacks.com/stock/news/2077704/why-abbvie-abbv-could-beat-earnings-estimates-again | AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. | Why AbbVie (ABBV) Could Beat Earnings Estimates Again | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-04-12 05:15:00 | https://www.fool.com/investing/2023/04/12/why-2023-could-be-a-tough-year-for-abbvie-stock/ | Humira's sales are forecast to fall by 37% this year. It may be years before Skyrizi and Rinvoq can make up for the Humira sales drop. | Why 2023 Could Be a Tough Year for AbbVie Stock | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2023-04-11 18:35:54 | https://www.youtube.com/watch?v=6MO8arZOYgk | The final trades of the day. With CNBC's Melissa Lee and the Fast Money traders. | Final Trades: Starbucks, Abbvie, Microsoft & APA Corp. | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2023-04-10 12:09:07 | https://www.zacks.com/stock/news/2076361/abbvie-abbv-j-j-to-withdraw-2-blood-cancer-nods-for-imbruvica | AbbVie (ABBV)/J&J's (JNJ) decision to withdraw the FDA's accelerated approval for Imbruvica in two blood cancer treatments is based on confirmatory studies data that do not support full approval. | AbbVie (ABBV), J&J to Withdraw 2 Blood Cancer Nods for Imbruvica | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-04-10 05:52:00 | https://www.fool.com/investing/2023/04/10/high-yield-dividend-stocks-warren-buffett-buy-now/ | Buffett's "secret portfolio" features stocks owned by Berkshire Hathaway subsidiary New England Asset Management. This portfolio includes two pharma stocks, two financial services stocks, and a telecom stock that offer high dividend yields. | 5 High-Yield Dividend Stocks in Warren Buffett's Secret Portfolio You Can Buy Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-04-09 03:20:02 | https://seekingalpha.com/article/4592997-dividend-champion-contender-challenger-highlights-week-april-9 | A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. | Dividend Champion, Contender, And Challenger Highlights: Week Of April 9 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-04-07 11:03:02 | https://seekingalpha.com/article/4592859-magic-formula-dividend-portfolio-april | The following is a dividend portfolio strategy for large caps that score the highest amongst Joel Greenblatt's Magic Formula screener. The list follows large caps that have dividends. | Magic Formula Dividend Portfolio For April | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Market Watch | 2023-04-05 17:21:00 | https://www.marketwatch.com/story/abbvie-lowers-guidance-after-150-million-charge-13481574 | Abbvie Inc. ABBV, +0.64% late Wednesday lowered its guidance for the year to include a charge of about $150 million. The pharma company said GAAP as well as adjusted earnings for its first quarter are expected to include expenses around in-progress research and development and milestones expenses resulting in the charg... | Abbvie lowers guidance after $150 million charge | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2023-04-05 13:57:12 | https://www.youtube.com/watch?v=zOyMEpA5aRc | The "Halftime Report" traders give their top picks to watch for the second half. | Final Trades: Abbvie, Thermo Fisher & more | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-04-05 08:55:00 | https://www.fool.com/investing/2023/04/05/better-dividend-stock-abbvie-vs-johnson-johnson/ | Both healthcare giants are among the most elite dividend stocks on the market. AbbVie can handle the biosimilar challenges to Humira without it breaking the company. | Better Dividend Stock: AbbVie vs. Johnson & Johnson | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-04-05 06:10:00 | https://www.fool.com/investing/2023/04/05/want-collect-big-dividends-month-buy-these-stocks/ | AbbVie's drug portfolio and pipeline bode well for future growth. Consumers value experiences more than stuff, which could benefit VICI Properties and its tenants. | Want to Collect Big Dividends Each Month? Buy These 3 Stocks | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2023-04-04 16:25:34 | https://www.gurufocus.com/news/1974421/a-look-at-bernard-horns-top-holdings-ahead-of-value-conference | With the goal of generating strong risk-adjusted returns and capital appreciation, Bernard Horn (Trades, Portfolio)'s Polaris Capital Management invests in discounted but high-quality stocks in developed as well as emerging markets. | A Look at Bernard Horn's Top Holdings Ahead of Value Conference | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2023-04-03 10:39:33 | https://www.zacks.com/stock/news/2073638/abbvie-inc-abbv-is-attracting-investor-attention-here-is-what-you-should-know | AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. | AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-04-02 05:50:00 | https://www.fool.com/investing/2023/04/02/high-yield-dividend-stocks-passive-income/ | Five stocks should generate an average yield of 8.45% on an investment of around $36,100. In addition to high dividend yields, these stocks offer attractive valuations and long-term growth prospects. | These 5 High-Yield Dividend Stocks Should Make Me $3,000 in Passive Income This Year | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-04-01 09:15:00 | https://www.fool.com/investing/2023/04/01/could-this-drug-news-lift-abbvies-stock/ | Rinvoq recently moved into phase 3 clinical trials for what could be its seventh indication. If approved, it could generate almost $400 million in additional yearly revenue for the drugmaker. | Could This Drug News Lift AbbVie's Stock? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-03-31 14:00:00 | https://seekingalpha.com/article/4591294-my-top-10-high-dividend-yield-stocks-to-invest-in-april-2023 | In today's article, I will present you with my top 10 high Dividend Yield stocks to invest in for April 2023. The 10 selected picks provide you with an attractive Dividend Yield, a relatively low Payout Ratio, as well as important competitive advantages and strong Financials. | My Top 10 High Dividend Yield Stocks To Invest In April 2023 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-03-31 08:50:00 | https://www.fool.com/investing/2023/03/31/this-blockbuster-drugs-latest-news-could-be-anothe/ | Skyrizi's recently announced phase 3 clinical trial results to treat ulcerative colitis demonstrate that it is effective. An ulcerative colitis indication in the U.S. could be a blockbuster all on its own. | This Blockbuster Drug's Latest News Could Be Another Home Run for AbbVie | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-03-30 07:45:00 | https://www.fool.com/investing/2023/03/30/2-high-yielding-dividend-investments-for-long-haul/ | Coca-Cola and AbbVie are two solid investments that pay more than 3% in dividends. Coca-Cola's growth rate has been impressive at a challenging time, and is well above its 10-year high. | 2 High-Yielding Dividend Investments to Buy for the Long Haul | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-03-29 14:00:00 | https://www.fool.com/investing/2023/03/29/better-growth-stock-vertex-pharmaceuticals-abbvie/ | Vertex and AbbVie both beat the bear market last year. Both these top companies have reached an important moment in their stories -- and more growth may be on the horizon. | Better Growth Stock: Vertex Pharmaceuticals vs. AbbVie | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-03-29 07:30:00 | https://www.fool.com/investing/2023/03/29/better-growth-stock-abbvie-vs-pfizer/ | AbbVie might not grow much in 2023 and 2024. Pfizer will see tens of billions of its sales evaporate soon. | Better Growth Stock: AbbVie vs. Pfizer | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-03-28 11:02:12 | https://seekingalpha.com/article/4590607-selecting-dividend-aristocrats-using-schd-methodology | I propose leveraging the stock selection criteria from the underlying index of SCHD to build a portfolio with a subset of Dividend Aristocrats. I am tracking two portfolios built using this process and comparing the results to NOBL and SCHD. | Selecting Dividend Aristocrats Using SCHD Methodology - Mounting A Comeback | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Stockmarketcom | 2023-03-28 10:43:54 | https://stockmarket.com/featured/best-stocks-to-buy-today-3-top-dividend-stocks-to-watch-2023-03-28 | Top dividend stocks to watch this week. | Best Stocks To Buy Today? 3 Top Dividend Stocks To Watch | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-03-28 10:07:00 | https://www.fool.com/investing/2023/03/28/2-relatively-safe-dividend-stocks-you-wont-regret/ | Companies that hike their dividends over and over tend to be financially healthy. AbbVie's good track record with commercializing medicines is likely to continue. | 2 Relatively Safe Dividend Stocks You Won't Regret Owning | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-03-28 08:13:00 | https://www.fool.com/investing/2023/03/28/this-is-the-best-dividend-etf-you-can-buy/ | ETFs provide stability and diversification to a portfolio. | This Is the Best Dividend ETF You Can Buy | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-03-25 05:30:00 | https://www.fool.com/investing/2023/03/25/better-buy-abbvie-vs-johnson-johnson/ | AbbVie and J&J both are facing big transitions this year. These stocks look inexpensive today, both trading at around 14 times forward earnings estimates. | Better Buy: AbbVie vs. Johnson & Johnson | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2023-03-24 14:28:09 | https://www.zacks.com/stock/news/2070329/abbvie-abbv-provides-clinical-updates-on-inflammatory-drugs | AbbVie???s (ABBV) two studies evaluating Skyrizi in ulcerative colitis and Rinvoq in systemic lupus erythematosus meet their primary endpoints. | AbbVie (ABBV) Provides Clinical Updates on Inflammatory Drugs | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2023-03-23 14:26:49 | https://www.youtube.com/watch?v=yelMS8qMgzI | The "Halftime Report" traders give their top picks to watch for the second half. | Final Trades: AbbVie, Nike, FedEx & more | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2023-03-23 11:27:33 | https://www.zacks.com/stock/news/2069633/abbvie-abbv-gets-fda-rejection-for-parkinson-s-candidate | In the CRL, the FDA asks AbbVie (ABBV) for some extra information about the pump device used to administer the Parkinson's disease medicine, ABBV-951. | AbbVie (ABBV) Gets FDA Rejection for Parkinson's Candidate | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-03-23 05:30:00 | https://www.fool.com/investing/2023/03/23/2-reasons-to-buy-abbvie-and-1-reason-to-sell/ | AbbVie's top-selling drug is facing competition -- and lower revenue. The company still has much to offer long-term investors. | 2 Reasons to Buy AbbVie, and 1 Reason to Sell | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2023-03-22 10:44:16 | https://www.zacks.com/stock/news/2068961/abbvie-inc-abbv-is-a-trending-stock-facts-to-know-before-betting-on-it | Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. | AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
MarketBeat | 2023-03-22 08:46:26 | https://www.marketbeat.com/originals/these-3-dividend-growers-yield-more-than-the-10-year-note/?SNAPI | Backed by the U.S. government, the closely watched 10-year Treasury note offers a high degree of safety that stocks and other investments can't match. What they no longer offer, however, is a 4% annualized interest rate. | These 3 Dividend Growers Yield More Than the 10-Year Note | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-03-17 02:28:00 | https://seekingalpha.com/article/4588153-february-2023-passive-income-good-times | This month was a fantastic month for dividend raises, adding a solid $101.39 to our forward income. While our dividend income is down, the overall passive income continues to increase. | February 2023 Passive Income - Good Times | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-03-16 08:30:00 | https://www.fool.com/investing/2023/03/16/2-growth-stocks-to-buy-before-bull-market-arrives/ | AbbVie's business is trading at a discount, and that's a mistake investors should pounce on. Nvidia's stock should continue to rally as PC sales strengthen and companies get back to upgrading IT. | 2 Growth Stocks to Buy Before the Bull Market Arrives | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-03-16 03:21:27 | https://seekingalpha.com/article/4587809-4-factor-dividend-growth-portfolio-first-insight | The 4-factor dividend growth portfolio was launched on November 1st, 2022, and is performing quite well. The portfolio lost by 34 bps to the S&P 500 Total Return during the month of February. | 4 Factor Dividend Growth Portfolio - First Insight | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
MarijuanaStocks | 2023-03-15 13:43:13 | https://marijuanastocks.com/marijuana-stocks-for-your-march-2023-watchlist/ | Here Are A Few Marijuana Stocks For Your Portfolio The post Marijuana Stocks For Your March 2023 Watchlist appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™. | Marijuana Stocks For Your March 2023 Watchlist | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-03-14 12:43:03 | https://seekingalpha.com/article/4587321-abbvie-comparing-current-valuation-to-last-growth-cycle | AbbVie is one of the most prominent biotechnology/healthcare stocks known for paying a good dividend. Besides the dividend, AbbVie didn't generate any returns on a one-year basis and is still a bit away from its all-time high. | AbbVie: Comparing The Current Valuation To Its Last Growth Cycle | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
MarketBeat | 2023-03-14 11:01:57 | https://www.marketbeat.com/originals/healthcare-stocks-with-at-least-30-years-of-dividend-increases/?SNAPI | While it is not the only factor to consider, the annual dividend can solidify whether a stock will benefit you financially. And among the many industry sectors to invest in, healthcare can be one of the most stable, especially regarding the dividend yield. | Healthcare Stocks With at Least 30 Years of Dividend Increases | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-03-14 07:44:19 | https://seekingalpha.com/article/4587223-weather-the-fed-with-abbvies-strong-portfolio-and-solid-dividend-growth | AbbVie's Humira sales may hold up better against biosimilars in the USA than they have in Europe. The pharmaceutical giant has a diverse portfolio of blockbuster drugs that should help to offset declining revenues in its leading therapies. | Weather The Fed With AbbVie's Strong Portfolio And Solid Dividend Growth | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-03-14 07:00:30 | https://www.fool.com/investing/2023/03/14/5-forever-dividend-stocks/ | These five dividend stocks make it a priority to return money to shareholders. | 5 Forever Dividend Stocks | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-03-14 03:17:24 | https://seekingalpha.com/article/4587174-abbvie-stock-dividend-yield-higher-growth-potential-buy | With the collapse of SVB Financial Group dominating the news and sending shockwaves again, we should look at recession-resilient companies like AbbVie. In fiscal 2022, AbbVie reported solid results, but growth slowed down. | AbbVie: With Banks In Distress, Look At Recession-Resilient Healthcare Companies | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2023-03-13 14:31:30 | https://www.youtube.com/watch?v=0nSAINHWfDk | The "Halftime Report" traders give their top picks to watch for the second half. | Final Trades: Oracle, Abbvie & Gold | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-03-11 09:00:00 | https://seekingalpha.com/article/4586321-the-near-perfect-portfolio-sleep-well-during-turbulent-times | The stock market is inherently volatile. With the economy going through the boom and bust cycles more frequently, the extreme ups and downs of the market are inevitable. For most conservative investors, especially retirees, it's very difficult to tolerate large and deep drawdowns. However, it is almost impossible to av... | The Near-Perfect Portfolio: Sleep Well During Turbulent Times | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2023-03-10 10:43:55 | https://www.zacks.com/stock/news/2064126/investors-heavily-search-abbvie-inc-abbv-here-is-what-you-need-to-know | AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. | Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2023-03-09 16:02:05 | https://www.zacks.com/commentary/2063771/reap-monthly-income-with-this-combination-of-3-stocks | While most stocks pay quarterly dividends, investors can still construct a portfolio that allows them to get paid monthly if they position themselves carefully. Who doesn't like payday? | Reap Monthly Income With This Combination of 3 Stocks | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-03-09 05:41:00 | https://www.fool.com/investing/2023/03/09/3-high-yield-dividend-stocks-to-buy-before-the-nex/ | Medical Properties Trust is a real estate investment trust that offers a huge 11.5% dividend yield. Ally Financial is an all-digital bank that offers a 4.1% yield at the moment. | 3 High-Yield Dividend Stocks to Buy Before the Next Bull Rally | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-03-09 05:30:00 | https://www.fool.com/investing/2023/03/09/is-it-too-late-to-buy-abbvie-stock/ | AbbVie expects U.S. sales of its blockbuster immunology drug Humira to decline 37% this year, as competition eats away at market share. But AbbVie's two newer immunology drugs could soon take over where Humira is leaving off. | Is It Too Late to Buy AbbVie Stock? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-03-07 12:48:04 | https://seekingalpha.com/article/4585266-abbvie-inc-abbv-cowen-43rd-annual-healthcare-conference-transcript | AbbVie Inc. (NYSE:ABBV ) Cowen 43rd Annual Healthcare Conference Call March 7, 2023 9:10 AM ET Company Participants Roopal Thakkar - Senior Vice President, Development and Regulatory Affairs and Chief Medical Officer Robert Michael - Vice Chairman and President Jeffrey Stewart - Executive Vice President and Chief Comme... | AbbVie Inc. (ABBV) Cowen 43rd Annual Healthcare Conference (Transcript) | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2023-03-06 16:51:35 | https://investorplace.com/2023/03/7-dividend-kings-to-buy-for-an-uncertain-market-environment/ | Though the term dividend aristocrats generate plenty of interest for the underlying elite status, another even more rarefied category exists called dividend kings to buy. Rather than 25 years of consecutive payout growth, the kings command at least 50 years. | 7 Dividend Kings to Buy for an Uncertain Market Environment | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-03-04 09:53:00 | https://www.fool.com/investing/2023/03/04/2-top-dividend-kings-to-buy-for-the-long-haul/ | These aren't just dividend plays, either. | 2 Top Dividend Kings to Buy for the Long Haul | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
24/7 Wall Street | 2023-03-02 22:55:25 | https://247wallst.com/investing/2023/03/02/5-best-and-worst-performing-mega-cap-stocks-in-february-2023/ | After a strong performance in January, the stock market lost pace in the second month of the year. | 5 Best and Worst Performing Mega-Cap Stocks in February 2023 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2023-03-02 12:47:22 | https://www.zacks.com/stock/news/2061122/rhhby-vs-abbv-which-stock-is-the-better-value-option | RHHBY vs. ABBV: Which Stock Is the Better Value Option? | RHHBY vs. ABBV: Which Stock Is the Better Value Option? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
MarketBeat | 2023-03-02 07:21:09 | https://www.marketbeat.com/originals/wall-street-sees-23-upside-in-revance-maker-of-botox-competitor/?SNAPI | Investors in Revance Therapeutics Inc. (NASDAQ: RVNC) shouldn't have much to frown about after the stock gapped up 54.34% on January 9, and built upon those gains in February. | Wall Street Sees 23% Upside In Revance, Maker Of Botox Competitor | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2023-03-01 14:28:42 | https://investorplace.com/2023/03/3-top-defensive-stocks-to-own-for-a-focus-on-quality/ | In today's volatile and uncertain market, investors increasingly seek stable, reliable, and resilient companies to add to their portfolios. Defensive stocks, which are typically associated with companies that operate in industries that provide essential goods and services, can provide a hedge against market downturns w... | 3 Top Defensive Stocks to Own for a Focus on Quality | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-02-28 18:55:22 | https://seekingalpha.com/article/4583060-march-dividend-kings-5-buys-4-to-watch | "There is only one-criterion to be included among the Dividend Kings: a publicly-traded company must increase its total fiscal-year dividend-payout for a minimum of 50 consecutive years."--Dogs of the Dow. The 47 Dividend Kings screened as of February 24, 2023, represented eight of eleven Morningstar Sectors. Broker ta... | March Dividend Kings: 5 Buys, 4 To Watch | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-02-27 09:20:00 | https://seekingalpha.com/article/4582375-recent-stock-purchasesale-february-2023 | There are two notable trades that are not buys this month as I decided to shuttle Haleon plc and GE HealthCare Technologies. Rarely does a spin-off these days equate to a solid real world standalone company. | Recent Stock Purchase/Sale February 2023 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2023-02-27 08:42:26 | https://investorplace.com/2023/02/3-high-yield-dividend-stocks-to-buy-and-hold-forever/ | High-yield dividend stocks offer relatively high dividend yields compared to the average dividend stock. Generally, I view a high-yield dividend to be above the 4-5% range. | 3 High-Yield Dividend Stocks to Buy and Hold Forever | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Stockmarketcom | 2023-02-25 15:44:12 | https://stockmarket.com/featured/3-biotech-stocks-to-watch-ahead-of-march-2023-2023-02-25 | Do you have these three biotech stocks on your watchlist right now? | 3 Biotech Stocks To Watch Ahead Of March 2023 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2023-02-23 06:30:24 | https://investorplace.com/2023/02/7-high-yield-dividend-stocks-that-are-monsters-poised-to-soar/ | When the U.S. central banks increased interest rates, investors needed to outperform the markets by buying high-yield dividend stocks. Investors are growing increasingly wary of buying companies whose stock would rise on their growth prospects. | 7 Dividend Yield Monsters Poised to Soar | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-02-22 19:42:51 | https://seekingalpha.com/article/4580876-selecting-dividend-aristocrats-using-schd-methodology-falling-behind | I propose leveraging the stock selection criteria from the underlying index of SCHD to build a portfolio with a subset of Dividend Aristocrats. I am tracking two portfolios built using this process and comparing the results to NOBL and SCHD. | Selecting Dividend Aristocrats Using SCHD Methodology - Falling Behind | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-02-22 09:39:00 | https://www.fool.com/investing/2023/02/22/want-to-get-to-1-million-by-retirement-heres-how-m/ | If you want to be a millionaire more quickly, you can always invest more along the way. | Want to Get to $1 Million by Retirement? Here's How Much You Should Invest Today. | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-02-22 07:30:00 | https://www.fool.com/investing/2023/02/22/want-more-reliable-dividend-income-buy-abbv-stock/ | This big pharma company possesses a deep drug portfolio and pipeline. | Want More Reliable Dividend Income? Buy This Dividend King. | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-02-20 07:25:00 | https://www.fool.com/investing/2023/02/20/3-top-dividend-kings-to-buy-for-the-long-haul/ | These companies have more than 150 years of dividend growth between them. | 3 Top Dividend Kings to Buy for the Long Haul | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-02-18 09:00:00 | https://www.fool.com/investing/2023/02/18/3-dividend-stocks-that-should-pay-you-the-rest-of/ | Each of these companies can provide income investors with growing, market-beating passive income. | 3 Dividend Stocks That Should Pay You the Rest of Your Life | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
MarketBeat | 2023-02-17 07:02:14 | https://www.marketbeat.com/originals/how-abbott-labs-abbvie-could-profit-on-seizure-drug-formula/?SNAPI | A new study published in Science Translational Medicine could introduce a profitable opportunity for makers of seizure drug medications. The discovery has immense medical implications, of course, but it could lead to a windfall for investors, particularly those holding Abbott Laboratories (NYSE: ABT) and AbbVie, Inc (N... | How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-02-16 09:10:00 | https://www.fool.com/investing/2023/02/16/is-this-the-start-of-a-nightmare-for-abbvie-stock/ | With a competitor set to devour market share, stormy waters might be ahead. | Is This the Start of a Nightmare for AbbVie Stock? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-02-16 01:08:45 | https://seekingalpha.com/article/4578846-competition-coming-for-abbvies-blockbuster-humira | It's among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie. | Competition Coming For AbbVie's Blockbuster Humira | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2023-02-15 15:49:23 | https://investorplace.com/2023/02/3-defensive-growth-stocks-to-load-up-on-in-q1/ | In this rather uncertain market, the search for defensive growth stocks is picking up. Indeed, this category of high-quality companies with steady cash flows and growing dividend distributions are sought out in times of turmoil. | 3 Defensive Growth Stocks to Load Up on in Q1 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-02-14 18:48:14 | https://seekingalpha.com/article/4578321-4-factor-dividend-growth-portfolio-january-2023-update | The 4 factor dividend growth portfolio was launched on November 1st, 2022, and is thus far off to a great start. The portfolio lost by 11 bps to the S&P 500 Total Return during the month of January. | 4 Factor Dividend Growth Portfolio - January 2023 Update | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2023-02-14 10:32:33 | https://www.zacks.com/stock/news/2053961/abbvie-inc-abbv-is-a-trending-stock-facts-to-know-before-betting-on-it | AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. | AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-02-14 09:07:00 | https://www.fool.com/investing/2023/02/14/3-of-the-best-dividend-growth-stocks/ | All three of these companies have consistently increased their dividends at a fast pace. | 3 of the BEST Dividend Growth Stocks | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-02-14 08:26:00 | https://www.fool.com/investing/2023/02/14/better-buy-johnson-johnson-or-abbvie/ | The healthcare giants are favored by income-oriented investors but have a potentially disruptive year ahead. | Better Buy: Johnson & Johnson or AbbVie? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2023-02-13 17:42:16 | https://investorplace.com/2023/02/the-7-most-undervalued-dividend-aristocrats-to-buy/ | If there's anything better than having at least some exposure to passive income-providing enterprises, it's loading the boat on the most undervalued dividend aristocrats to buy. Per Investopedia, “[d]ividend aristocrats are stocks of companies that have raised their dividends for at least 25 consecutive years. | The 7 Most Undervalued Dividend Aristocrats to Buy | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
MarketBeat | 2023-02-13 07:00:17 | https://www.marketbeat.com/originals/abbvie-has-a-mixed-outlook-after-mixed-earnings/?SNAPI | AbbVie Inc. (NYSE: ABBV) stock is back to where it started after the day after posting a mixed fourth-quarter earnings report. The company delivered a slight beat on expected earnings but came in light on the top line. | AbbVie Has a Mixed Outlook After Mixed Earnings | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-02-11 09:30:00 | https://seekingalpha.com/article/4577402-the-dividend-aristocrats-ranked-by-quality-scores | The annual rebalancing and subsequent changes to the S&P 500 Dividend Aristocrats Index have produced a new list of 67 dividend growth stocks called the Dividend Aristocrats. I rank the Dividend Aristocrats using Quality Snapshots, an elegant and effective system for assessing the quality of dividend growth stocks. | The Dividend Aristocrats Ranked By Quality Scores | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-02-11 09:00:00 | https://seekingalpha.com/article/4576769-how-this-income-method-could-lead-to-financial-freedom | We will go over our thesis as to how a diversified income method with low volatility could make you financially independent. We regularly write about multi-basket income strategies with an in-built hedging mechanism to keep the drawdowns to a minimum. They provide not only consistent income but also long-term growth wi... | How This Income Method Could Lead To Financial Freedom | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-02-11 06:00:00 | https://www.fool.com/investing/2023/02/11/heres-exactly-how-abbvie-stock-can-beat-the-market/ | Don't think the challenges for Humira doom AbbVie to a sub-par stock performance this year. | Here's Exactly How AbbVie Stock Can Beat the Market In 2023 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-02-10 13:00:30 | https://seekingalpha.com/article/4577351-abbvie-a-4-percent-yield-plus-potential-upside-whats-not-to-like | We share another of the 22 Mega Cap stocks with the prospect of higher prices in 2023. Lyn Alden provides important insight into the fundamental terrain on which AbbVie Inc. currently sits. | AbbVie: A 4% Yield Plus Potential Upside - What's Not To Like? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Investors Business Daily | 2023-02-10 10:52:34 | https://www.investors.com/news/technology/abbvie-stock-sidesteps-draconian-expectations-for-humira-dropoff/ | AbbVie stock won at least one upgrade Friday after issuing long-awaited guidance for Humira for the first year it faces new competition. The post AbbVie's Humira: The Downfall Won't Be As 'Draconian' As Initially Expected appeared first on Investor's Business Daily. | AbbVie's Humira: The Downfall Won't Be As 'Draconian' As Initially Expected | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2023-02-10 10:32:37 | https://www.zacks.com/stock/news/2052843/compared-to-estimates-abbvie-abbv-q4-earnings-a-look-at-key-metrics | While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. | Compared to Estimates, AbbVie (ABBV) Q4 Earnings: A Look at Key Metrics | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-02-09 17:02:03 | https://seekingalpha.com/article/4577016-abbvie-inc-abbv-q4-2022-earnings-call-transcript | AbbVie Inc. (NYSE:ABBV ) Q4 2022 Earnings Conference Call February 9, 2023 9:00 AM ET Company Participants Liz Shea - Vice President of Investor Relations Rick Gonzalez - Chairman & Chief Executive Officer Jeff Stewart - Executive Vice President & Chief Commercial Officer Carrie Strom - Senior Vice President & Presiden... | AbbVie Inc. (ABBV) Q4 2022 Earnings Call Transcript | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2023-02-09 15:34:28 | https://www.youtube.com/watch?v=ANa558FAQNQ | The Wall Street Journal's Jared Hopkins joins 'Power Lunch' to discuss biotech patent protection duration, competition coming to the pharmaceutical industry and pharmaceutical M&A plans. | Pharmaceutical companies losing patent protection as competition grows | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
WSJ | 2023-02-09 12:58:00 | https://www.wsj.com/articles/the-end-of-abbvies-200-billion-monopoly-wont-sink-the-stock-11675965537 | The drugmaker is offering steep discounts on its immune-disease therapy Humira to protect market share this year. | The End of Abbvie's $200 Billion Monopoly Won't Sink the Stock | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Stockmarketcom | 2023-02-09 12:53:50 | https://stockmarket.com/featured/what-stocks-to-buy-today-3-dividend-stocks-to-watch-after-earnings-2023-02-09 | Are these the best dividend stocks to buy today? | What Stocks to Buy Today? 3 Dividend Stocks To Watch After Earnings | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2023-02-09 12:49:30 | https://www.zacks.com/stock/news/2052457/abbvie-abbv-beats-q4-earnings-estimates-misses-on-sales | AbbVie's Q4 earnings (ABBV) beat estimates, while sales miss the same. Full-year 2023 EPS falls short of estimates. | AbbVie (ABBV) Beats Q4 Earnings Estimates, Misses on Sales | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2023-02-09 10:34:30 | https://www.zacks.com/stock/news/2052237/abbvie-abbv-q4-earnings-beat-estimates | AbbVie (ABBV) delivered earnings and revenue surprises of 1.69% and 1.52%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? | AbbVie (ABBV) Q4 Earnings Beat Estimates | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-02-09 09:10:00 | https://www.fool.com/investing/2023/02/09/do-humira-biosimilars-threaten-abbvies-dividend/ | Generic competition will eat at Humira's roughly $20 billion in annual sales. | Do Humira Biosimilars Threaten AbbVie's Dividend? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Barrons | 2023-02-09 08:47:00 | https://www.barrons.com/articles/abbvie-earnings-humira-sales-51675950222 | AbbVie says international sales of Humira in the fourth quarter fell 26.5% from a year earlier. | AbbVie Posts an Earnings Beat but Forecast Misses as Competition Intensifies | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Market Watch | 2023-02-09 08:04:00 | https://www.marketwatch.com/story/abbvies-stock-gains-on-q4-results-01675947861 | Shares of AbbVie Inc. ABBV, -0.37% gained 2.4% in premarket trading on Thursday after the company beat earnings expectations for the fourth quarter of 2022. AbbVie had a profit of $2.4 billion, or $1.38 per share, in the fourth quarter of 2022, down from $4.0 billion, or $2.26 per share, in the same quarter in 2021. | AbbVie's stock gains on Q4 results | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-02-08 08:30:00 | https://seekingalpha.com/article/4576131-4-dividend-aristocrat-buys-for-february | "Dividend Aristocrats in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years." - Kiplinger.com/Investing. By yield, VFC topped all Aristocrats. Top-ten yields from TROW, ESS, FRT, AMCR, ABBV, O, IBM, MMM, WBA, & VFC, averaged 4.38%. | 4 Dividend Aristocrat Buys For February | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2023-02-07 13:33:20 | https://www.zacks.com/stock/news/2051155/will-abbvie-s-abbv-new-drugs-continue-to-drive-q4-earnings | AbbVie's (ABBV) fourth-quarter performance is expected to reflect the impact of strong demand for immunology and neuroscience products. | Will AbbVie's (ABBV) New Drugs Continue to Drive Q4 Earnings? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-02-07 07:15:00 | https://seekingalpha.com/article/4575642-hedge-funds-love-these-8-dividend-blue-chips-and-so-should-you | Hedge funds employ some of the world's brightest analysts, with the most resources for analyzing companies. Lists of the most widely owned blue-chips among hedge funds can be a good source of new investing ideas. | Hedge Funds Love These 8 Dividend Blue Chips, And So Should You | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-02-06 16:48:16 | https://seekingalpha.com/article/4575703-wall-street-analysts-and-options-market-suggest-abbvie-has-upside | There is widespread concern about the impact of Humira biosimilars being available in the U.S. The consensus outlook is that ABBV's earnings will decline. | Wall Street Analysts And Options Market Suggest AbbVie Has Upside | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-02-06 07:30:00 | https://seekingalpha.com/article/4575487-is-abbvie-stock-buy-following-share-price-slump | AbbVie has seen its shares pull back in recent weeks. Humira has gone off patent in the US, but other assets are generating strong growth. | Is AbbVie A Buy Following The Share Price Slump? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
WSJ | 2023-02-06 05:30:00 | https://www.wsj.com/articles/abbvie-aims-for-new-drugs-to-boost-sales-as-competitors-target-humira-11675638126 | Drugmaker is turning to next-generation successors to Humira to replenish billions of dollars in sales that will be lost, and lifting a self-imposed $2 billion limit on the size of deals it would do to add products. | AbbVie Aims for New Drugs to Boost Sales as Competitors Target Humira | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-02-05 17:00:00 | https://seekingalpha.com/article/4575440-abbvie-dreaded-humira-cliff-here-time-to-sell | The day has arrived: Biosimilars for the blockbuster drug Humira are now being sold in the US. AbbVie investors are rightfully apprehensive, although the company has prepared for this day for years. | AbbVie: The Dreaded Humira Cliff Is Here: Time To Sell? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.